Articles

Find an Article

Filter articles

Applied Filters

Showing 231 to 240 of 272 results

A changing market: Genomic Vision's IP strategy

EU, France04-11-2013

Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out.

New frontiers: potential barriers to patenting induced totipotent stem cell technology

EU04-11-2013

Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson.

Adapt or die: how to survive the patent cliff

India, US16-10-2013

Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.

Protecting plant products in Europe

EU16-10-2013Frances Salisbury and Lindsey Woolley

Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.

Patents for self-replicating products: not so exhausting after all

EU16-10-2013

When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke.

Enough is enough: sufficiency and technical contribution

EU, US16-10-2013

In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.

Salad days: tomatoes, broccoli and radish patents

EU16-10-2013Margreet van Heuvel and Bart Swinkels

When it comes to plants, European courts have been occupied with various debates over salad. Margreet van Heuvel and Bart Swinkels take a look.

'Because he fears': should generics fear the high court's quia timet injunctions?

UK16-10-2013Bethan Hopewell and Geraldine Quinn

For generic drug makers, previous bad behaviour may affect new litigation, especially when it comes to injunctions, as Bethan Hopewell and Geraldine Quinn explain.

A giant's perspective: interview with Bayer

Germany, India16-10-2013

LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world.

Courting controversy: the implications of Brüstle

EU, Germany16-10-2013

The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe.

Showing 231 to 240 of 272 results

LSIPR